[1]Luis P, et al. TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). 2023 ESMO 1314MO. [2] Lisberg AE, et ...
ALINA研究:阿来替尼 vs. 化疗辅助治疗早期ALK融合+ NSCLC患者的疗效和安全性[4] ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC) 摘要号:LBA2 ...
[7]National Comprehensive Cancer Network. Non-small cell lung cancer NCCN guidelines version 1.2022[EB/OL]. [2021-10-25].https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 往期回顾丨淼淼的其他精彩文章 出现放射性肺炎不要慌,防治要点在这里 肺癌...
In this article, we summarize our personal non-small cell lung cancer (NSCLC) highlights from the ESMO 2022 meeting, covering developments in early- and advanced-stage NSCLC. In early-stage disease, many studies underlined possibilities of neoadjuvant and adjuvant treatment, including neoadjuvant ...
ESMO:540P-Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy. 本届会议恩曲替尼公布了多项研究数据,包括对3项Ⅰ/Ⅱ期临床试验的综合分析(543P),结果显示恩曲替尼在NTRK和ROS1融合...
[1]J.D.Spicer,etal.OverallsurvivalintheKEYNOTE-671studyofperioperativepembrolizumabforear-ly-stagenon-small-celllungcancer(非小细胞肺癌).2023ESMO.LBA56. [2]AlbertoF.Sobrero,etal:ASCOGI2023.PosterSession67. [3]LBA59AssociationsofctDNAclearanceandpathologicalresponsewithneoadjuvanttreatmentinpatientswithrese...
【舒格利单抗获ESMO指南非小细胞肺癌双适应症一线治疗推荐】2025年2月10日,基石药业宣布,抗PD-L1单克隆抗体「舒格利单抗」被纳入《欧洲肿瘤内科学会非驱动基因阳性转移性非小细胞肺癌动态临床指南》(ESMO Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline),同时成为鳞状及非鳞状非小细胞...
9. LBA54 - Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutated, Advanced Non-small Cell Lung Cancer After Disease Progression on Osimertinib: 2nd Interim Overall Survival From MARIPOSA-2 LBA54 - 在奥希替尼治疗疾病进展后的EGFR突变、晚期非小细胞肺癌中,amivantamab联合化疗与化疗的比较:MARIP...
1.Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up...
TROPION-Lung05:datopotamab deruxtecan(Dato-DXd)治疗既往经治的具有可靶向基因组改变(AGA)的NSCLC 摘要号:1315MO 标题:Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) ...